Korro Bio vs Silence Therapeutics
KRRO and SLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRRO and SLN compare
Korro Bio grew revenue faster over the last twelve months (−82.5% versus −97.7% for Silence Therapeutics).
Korro Bio keeps more of each dollar of sales as profit, with a net margin of −8214% compared with −9748% at Silence Therapeutics.
Silence Therapeutics scores higher on the StockData Score (6 against 5 for Korro Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRRO | SLN |
|---|---|---|
| Size and price | ||
| Market cap | $211M | – |
| Share price | $14.31 | $19.80 |
| Change, 1 year | −56.4% | 195% |
| Change, 5 years | −95.2% | −13.7% |
| Beta (5Y) | 2.09 | 1.05 |
| Employees | 58 | 88 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 163× | – |
| FCF yield | −30.3% | – |
| Growth | ||
| Revenue growth (TTM) | −82.5% (better) | −97.7% |
| Revenue growth, 5Y average | −29.6% | – |
| Profitability | ||
| Gross margin | – | 85.9% |
| Operating margin | −8467% (better) | −11107% |
| Net margin | −8214% (better) | −9748% |
| FCF margin | −4944% (better) | −6873% |
| Return on equity | – | −90.4% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 7.30 | 7.42 (better) |
| Altman Z-score | −3.71 | – |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 102% | 16.6% |
| Held by insiders | 27.5% | 48.1% |
| Insider net buying, 12 months | $16.0M | – |
| Short interest, % of float | 16.4% | – |
Go deeper
- KRRO stock overview
- KRRO income statement
- KRRO valuation and score
- SLN stock overview
- SLN income statement
- SLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.